While a subset of these resistant tumors differentiates into an AR-negative neuroendocrine state (~15–20%), the vast majority of CRPC tumors still remain dependent on AR signaling even when the cancer has been treated with potent AR pathway inhibitors (ARPIs) including enzalutamide, abiraterone, or apalutamide (5–11). Here, AR is linked to cancer.